Urology

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study (European Urology Oncology)

19 september 2019 23:00:17

This prospective study suggests that radical metastasectomy could improve the clinical outcome of selected patients with metastatic renal cell carcinoma, while the addition of sorafenib did not increase recurrence-free survival.

239 viewsCategory: Oncology, Urology

Complications and Adverse Events of Three Magnetic Resonance Imaging-based Target Biopsy Techniques in the Diagnosis of Prostate Cancer Among Men with Prior Negative Biopsies: Results from the FUTURE Trial, a Multicentre Randomised Controlled Trial (European Urology Oncology)
Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators (European Urology Oncology)

blog comments powered by Disqus

MyJournals.org
The latest issues of all your favorite science journals on one page

Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study (European Urology Oncology)

19 september 2019 23:00:17

Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice. Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten

Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten